Novo Nordisk ’s New Obesity Pill Beats Wegovy In Early Trial
Shares of Novo Nordisk reached a record high after the company released promising data for amycretin, a new weight loss pill.
Source: Forbes.com Healthcare News - Category: Pharmaceuticals Authors: Robert Hart, Forbes Staff Tags: Business /business Innovation /innovation Healthcare /healthcare Science /science Breaking breaking-news topline Source Type: news